Draft:OpenEvidence
Submission declined on 9 August 2025 by Stuartyeates (talk).
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Comment: Literally none of these sources are independent and many of the claims appear to be hallucinations. Stuartyeates (talk) 21:49, 9 August 2025 (UTC)
 | This is a draft article. It is a work in progress open to editing by anyone. Please ensure core content policies are met before publishing it as a live Wikipedia article. Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL Last edited by Stuartyeates (talk | contribs) 1 second ago. (Update)
Finished drafting? |
| Company type | Private |
|---|---|
| Industry |
|
| Founded | 2021 |
| Founders |
|
Key people | Daniel Nadler (CEO) |
| Products |
|
| Website | www |
OpenEvidence, Inc. is an American medical artificial intelligence (AI) company. Its platform allows verified physicians to search across more than 35 million peer‑reviewed publications and receive referenced answers at the point of care.[1][2] As of July 2025 the system is used daily by over 40 percent of U.S. physicians and in more than 10,000 hospitals and medical centers.[3][2]
History
[edit]Harvard-trained AI scientists Daniel Nadler and Zachary Ziegler founded OpenEvidence in 2021 in Cambridge, Massachusetts.[4][5] In 2025, the company moved its headquarters to Miami, Florida.[6]
A $75 million Series A led by Sequoia Capital in February 2025 valued the company at $1 billion.[4] In July 2025, OpenEvidence announced a $210 million Series B co-led by GV and Kleiner Perkins, raising its valuation to $3.5 billion and bringing total funding to more than $300 million.[7][8]
Partnerships
[edit]OpenEvidence has licensing agreements with major publishers, including The New England Journal of Medicine and JAMA and its eleven specialty journals, allowing full‑text material to inform answers.[3][1]
Reception
[edit]Observers have compared the platform's impact to Google's effect on general web search.[8][9] John Doerr of Kleiner Perkins described it as “a life‑saving resource for doctors, patients and their families" and said “I think OpenEvidence looks like it's going to be for healthcare what Google was for the Internet.”[8]
See also
[edit]References
[edit]- ^ a b "Partnering with OpenEvidence". Coatue. 16 June 2025. Retrieved 26 July 2025.
- ^ a b "OpenEvidence: Expanding the world's collective medical knowledge". Kleiner Perkins. 15 July 2025. Retrieved 26 July 2025.
- ^ a b Zeb, Sangeen (15 July 2025). "OpenEvidence: The Leading AI App for Doctors". GV. Retrieved 26 July 2025.
- ^ a b Rooney, Kate (19 February 2025). "AI health‑care startup OpenEvidence raises funding from Sequoia at $1 billion valuation". CNBC. Retrieved 26 July 2025.
- ^ "OpenEvidence raises $210M on $3.5B valuation to expand AI‑powered medical search and decision tools". SiliconANGLE. 15 July 2025. Retrieved 26 July 2025.
- ^ Feldman, Amy. "OpenEvidence Cofounder Daniel Nadler Is Now A Billionaire". Forbes. Retrieved 2025-07-26.
- ^ "OpenEvidence, the Fastest‑Growing Application for Physicians in History, Announces $210 Million Round at $3.5 Billion Valuation" (Press release). OpenEvidence. 15 July 2025. Retrieved 26 July 2025.
- ^ a b c Feldman, Amy (15 July 2025). "This AI Founder Became A Billionaire By Building ChatGPT For Doctors". Forbes. Retrieved 26 July 2025.
- ^ "Partnering with OpenEvidence: A Life‑Saving Healthcare Revolution". Sequoia Capital. 19 February 2025. Retrieved 26 July 2025.
External links
[edit]
- in-depth (not just passing mentions about the subject)
- reliable
- secondary
- independent of the subject
Make sure you add references that meet these criteria before resubmitting. Learn about mistakes to avoid when addressing this issue. If no additional references exist, the subject is not suitable for Wikipedia.